SYRESpyre Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$210M
- 0.5% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $19M | $2M | $886K | $0 | $0 | |
| Operating income | −$66M | −$85M | −$242M | −$209M | −$210M | 0.5% |
| Net income | −$66M | −$84M | −$339M | −$208M | −$155M | 25% |
| Operating cash flow | −$54M | −$80M | −$100M | −$157M | −$169M | 7.5% |
| Capex | $573K | $38K | $0 | $0 | — | |
| Stock-based comp | $8M | $7M | $26M | $45M | $38M | 16% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $6M · 17
- Net
- −$6M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 17 | 125 |
| FY2024 | — | — | 12 | 93 |
| FY2023 | — | — | 11 | 94 |
| FY2022 | — | — | 6 | 90 |
| FY2021 | — | — | 60 | 100 |